{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T11:13:35Z","timestamp":1769166815663,"version":"3.49.0"},"reference-count":37,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2009,3,1]],"date-time":"2009-03-01T00:00:00Z","timestamp":1235865600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["jpet.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"published-print":{"date-parts":[[2009,3]]},"DOI":"10.1124\/jpet.108.145508","type":"journal-article","created":{"date-parts":[[2008,11,25]],"date-time":"2008-11-25T02:37:08Z","timestamp":1227580628000},"page":"893-899","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":36,"title":["Comparison of Receptor Binding Characteristics of Commonly Used Muscarinic Antagonists in Human Bladder Detrusor and Mucosa"],"prefix":"10.1016","volume":"328","author":[{"given":"Kylie J.","family":"Mansfield","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jonathan J.","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kenneth J.","family":"Vaux","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richard J.","family":"Millard","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Arthur","family":"Christopoulos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Frederick J.","family":"Mitchelson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Elizabeth","family":"Burcher","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1124\/jpet.108.145508_bib1","doi-asserted-by":"crossref","unstructured":"Abrams P and Andersson KE (2007) Muscarinic receptor antagonists for overactive bladder. BJU Int 100: 987-1006.","DOI":"10.1111\/j.1464-410X.2007.07205.x"},{"key":"10.1124\/jpet.108.145508_bib2","doi-asserted-by":"crossref","unstructured":"Andersson KE and Yoshida M (2003) Antimuscarinics and the overactive detrusor-Which is the main mechanism of action? Eur Urol 43: 1-5.","DOI":"10.1016\/S0302-2838(02)00540-7"},{"key":"10.1124\/jpet.108.145508_bib3","doi-asserted-by":"crossref","unstructured":"Brubaker L (2004) Urgency: the cornerstone symptom of overactive bladder. Urology 64: 12-16.","DOI":"10.1016\/j.urology.2004.10.073"},{"key":"10.1124\/jpet.108.145508_bib4","doi-asserted-by":"crossref","unstructured":"Bschleipfer T, Schukowski K, Weidner W, Grando SA, Schwantes U, Kummer W, and Lips KS (2007) Expression and distribution of cholinergic receptors in the human urothelium. Life Sci 80: 2303-2307.","DOI":"10.1016\/j.lfs.2007.01.053"},{"key":"10.1124\/jpet.108.145508_bib5","doi-asserted-by":"crossref","unstructured":"Chapple CR, Rechberger T, Al-Shukri S, Meffan P, Everaert K, Huang M, and Ridder A (2004) Randomised, double-blind placebo- and tolterodine-controlled trial of the once-daily antimuscarinic agent solifenacin in patients with symptomatic overactive bladder. BJU Int 93: 303-310.","DOI":"10.1111\/j.1464-410X.2004.04606.x"},{"key":"10.1124\/jpet.108.145508_bib6","doi-asserted-by":"crossref","unstructured":"Colli E, Digesu GA, and Olivieri L (2007) Overactive bladder treatments in early phase clinical trials. Expert Opin Investig Drugs 16: 999-1007.","DOI":"10.1517\/13543784.16.7.999"},{"key":"10.1124\/jpet.108.145508_bib7","doi-asserted-by":"crossref","unstructured":"D\u2019Agostino G, Bolognesi ML, Lucchelli A, Vicini D, Balestra B, Spelta V, Melchiorre C, and Tonini M (2000) Prejunctional muscarinic inhibitory control of acetylcholine release in the human isolated detrusor: involvement of M4 receptor subtype. Br J Pharmacol 129: 493-500.","DOI":"10.1038\/sj.bjp.0703080"},{"key":"10.1124\/jpet.108.145508_bib8","doi-asserted-by":"crossref","unstructured":"De Laet K, De Wachter S, and Wyndaele JJ (2006) Systemic oxybutynin decreases afferent activity of the pelvic nerve of the rat: new insights into the working mechanism of antimuscarinics. Neurourol Urodyn 25: 156-161.","DOI":"10.1002\/nau.20208"},{"key":"10.1124\/jpet.108.145508_bib9","doi-asserted-by":"crossref","unstructured":"De Wachter S and Wyndaele JJ (2003) Intravesical oxybutynin: a local anaesthetic effect on bladder C afferents. J Urol 169: 1892-1895.","DOI":"10.1097\/01.ju.0000049903.60057.4b"},{"key":"10.1124\/jpet.108.145508_bib10","doi-asserted-by":"crossref","unstructured":"Enzelsberger H, Helmer H, and Kurz C (1995) Intravesical instillation of oxybutynin in women with idiopathic detrusor instability: a randomised trial. Br J Obstet Gynaecol 102: 929-930.","DOI":"10.1111\/j.1471-0528.1995.tb10885.x"},{"key":"10.1124\/jpet.108.145508_bib11","doi-asserted-by":"crossref","unstructured":"Ferguson DR, Kennedy I, and Burton TJ (1997) ATP is released from rabbit urinary bladder epithelial cells by hydrostatic pressure changes-a possible sensory mechanism? J Physiol 505: 503-511.","DOI":"10.1111\/j.1469-7793.1997.503bb.x"},{"key":"10.1124\/jpet.108.145508_bib12","doi-asserted-by":"crossref","unstructured":"Finney SM, Andersson KE, Gillespie JI, and Stewart LH (2006) Antimuscarinic drugs in detrusor overactivity and the overactive bladder syndrome: motor or sensory actions? BJU Int 98: 503-507.","DOI":"10.1111\/j.1464-410X.2006.06258.x"},{"key":"10.1124\/jpet.108.145508_bib13","doi-asserted-by":"crossref","unstructured":"Freeman R, Hill S, Millard R, Slack M, and Sutherst J (2003) Reduced perception of urgency in treatment of overactive bladder with extended-release tolterodine. Obstet Gynecol 102: 605-611.","DOI":"10.1097\/00006250-200309000-00033"},{"key":"10.1124\/jpet.108.145508_bib14","unstructured":"Fr\u00f6hlich G, Burmeister S, Wiedemann A, and Bulitta M (1998) Intravesical instillation of trospium chloride, oxybutynin and verapamil for relaxation of the bladder detrusor muscle. A placebo controlled, randomised clinical test. Arzneimittelforschung 48: 486-491."},{"key":"10.1124\/jpet.108.145508_bib15","doi-asserted-by":"crossref","unstructured":"Fry CH, Ikeda Y, Harvey R, Wu C, and Sui GP (2004) Control of bladder function by peripheral nerves: avenues for novel drug targets. Urology 63: 24-31.","DOI":"10.1016\/j.urology.2003.10.031"},{"key":"10.1124\/jpet.108.145508_bib16","doi-asserted-by":"crossref","unstructured":"Hanna-Mitchell AT, Beckel JM, Barbadora S, Kanai AJ, de Groat WC, and Birder LA (2007) Non-neuronal acetylcholine and urinary bladder urothelium. Life Sci 80: 2298-2302.","DOI":"10.1016\/j.lfs.2007.02.010"},{"key":"10.1124\/jpet.108.145508_bib17","doi-asserted-by":"crossref","unstructured":"Hegde SS (2006) Muscarinic receptors in the bladder: from basic research to therapeutics. Br J Pharmacol 147: S80-S87.","DOI":"10.1038\/sj.bjp.0706560"},{"key":"10.1124\/jpet.108.145508_bib18","doi-asserted-by":"crossref","unstructured":"Iijima K, De Wachter S, and Wyndaele JJ (2007) Effects of the M3 receptor selective muscarinic antagonist darifenacin on bladder afferent activity of the rat pelvic nerve. Eur Urol 52: 842-847.","DOI":"10.1016\/j.eururo.2007.02.057"},{"key":"10.1124\/jpet.108.145508_bib19","doi-asserted-by":"crossref","unstructured":"Kim Y, Yoshimura N, Masuda H, de Miguel F, and Chancellor MB (2005) Antimuscarinic agents exhibit local inhibitory effects on muscarinic receptors in bladder-afferent pathways. Urology 65: 238-242.","DOI":"10.1016\/j.urology.2004.11.021"},{"key":"10.1124\/jpet.108.145508_bib20","doi-asserted-by":"crossref","unstructured":"Lanzafame AA, Sexton PM, and Christopoulos A (2006) Interaction studies of multiple binding sites on M4 muscarinic acetylcholine receptors. Mol Pharmacol 70: 736-746.","DOI":"10.1124\/mol.106.024711"},{"key":"10.1124\/jpet.108.145508_bib21","doi-asserted-by":"crossref","unstructured":"Madersbacher H and Jilg G (1991) Control of detrusor hyperreflexia by the intravesical instillation of oxybutynin hydrochloride. Paraplegia 29: 84-90.","DOI":"10.1038\/sc.1991.11"},{"key":"10.1124\/jpet.108.145508_bib22","doi-asserted-by":"crossref","unstructured":"Masuda H, Kim YT, Tyagi S, Chancellor MB, de Miguel F, and Yoshimura N (2006) Local effects of antimuscarinics. Urol Clin North Am 33: 511-518, ix-x.","DOI":"10.1016\/j.ucl.2006.06.011"},{"key":"10.1124\/jpet.108.145508_bib23","doi-asserted-by":"crossref","unstructured":"Mansfield KJ, Liu L, Mitchelson FJ, Moore KH, Millard RJ, and Burcher E (2005) Muscarinic receptor subtypes in human bladder detrusor and mucosa, studied by radioligand binding and quantitative competitive RT-PCR: changes with ageing. Br J Pharmacol 144: 1089-1099.","DOI":"10.1038\/sj.bjp.0706147"},{"key":"10.1124\/jpet.108.145508_bib24","doi-asserted-by":"crossref","unstructured":"May LT, Avlani VA, Langmead CJ, Herdon HJ, Wood MD, Sexton PM, and Christopoulos A (2007) Structure-function studies of allosteric agonism of M2 muscarinic acetylcholine receptors. Mol Pharmacol 72: 463-476.","DOI":"10.1124\/mol.107.037630"},{"key":"10.1124\/jpet.108.145508_bib25","doi-asserted-by":"crossref","unstructured":"Millard RJ and Halaska M (2006) Efficacy of solifenacin in patients with severe symptoms of overactive bladder: a pooled analysis. Curr Med Res Opin 22: 41-48.","DOI":"10.1185\/030079905X74907"},{"key":"10.1124\/jpet.108.145508_bib26","doi-asserted-by":"crossref","unstructured":"Milsom I, Abrams P, Cardozo L, Roberts RG, Th\u00fcroff J, and Wein AJ (2001) How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 87: 760-766.","DOI":"10.1046\/j.1464-410x.2001.02228.x"},{"key":"10.1124\/jpet.108.145508_bib27","doi-asserted-by":"crossref","unstructured":"Michel MC and Hegde SS (2006) Treatment of the OAB syndrome with muscarinic receptor antagonists: a matter of metabolites? Naunyn Schmiedebergs Arch Pharmacol 374: 79-85.","DOI":"10.1007\/s00210-006-0105-y"},{"key":"10.1124\/jpet.108.145508_bib28","doi-asserted-by":"crossref","unstructured":"Mukerji G, Yiangou Y, Grogono J, Underwood J, Agarwal SK, Khullar V, and Anand P (2006) Localization of M2 and M3 muscarinic receptors in human bladder disorders and their clinical correlations. J Urol 176: 367-373.","DOI":"10.1016\/S0022-5347(06)00563-5"},{"key":"10.1124\/jpet.108.145508_bib29","doi-asserted-by":"crossref","unstructured":"Ney P, Pandita RK, Newgreen DT, Breidenbach A, St\u00f6hr T, and Andersson KE (2008) Pharmacological characterisation of a novel investigational antimuscarinic drug, fesoterodine, in vitro and in vivo. BJU Int 101: 1036-1042.","DOI":"10.1111\/j.1464-410X.2007.07358.x"},{"key":"10.1124\/jpet.108.145508_bib30","doi-asserted-by":"crossref","unstructured":"Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R, Hunt TL, and Wein AJ (2003) Prevalence and burden of overactive bladder in the United States. World J Urol 20: 327-336.","DOI":"10.1007\/s00345-002-0301-4"},{"key":"10.1124\/jpet.108.145508_bib31","doi-asserted-by":"crossref","unstructured":"Tyagi S, Tyagi P, Van-le S, Yoshimura N, Chancellor MB, and de Miguel F (2006) Qualitative and quantitative expression profile of muscarinic receptors in human urothelium and detrusor. J Urol 176: 1673-1678.","DOI":"10.1016\/j.juro.2006.06.088"},{"key":"10.1124\/jpet.108.145508_bib32","doi-asserted-by":"crossref","unstructured":"Wagg A, Wyndaele JJ, and Sieber P (2006) Efficacy and Tolerability of Solifenacin in Elderly Subjects with Overactive Bladder Syndrome: A Pooled Analysis. Am J Geriatr Pharmacother 4: 14-24.","DOI":"10.1016\/j.amjopharm.2006.03.004"},{"key":"10.1124\/jpet.108.145508_bib33","doi-asserted-by":"crossref","unstructured":"Walter P, Grosse J, Bihr AM, Kramer G, Schulz HU, Schwantes U, and St\u00f6hrer M (1999) Bioavailability of trospium chloride after intravesical instillation in patients with neurogenic lower urinary tract dysfunction: a pilot study. Neurourol Urodyn 18: 447-453.","DOI":"10.1002\/(SICI)1520-6777(1999)18:5<447::AID-NAU6>3.3.CO;2-H"},{"key":"10.1124\/jpet.108.145508_bib34","doi-asserted-by":"crossref","unstructured":"Yokoyama O, Yusup A, Miwa Y, Oyama N, Aoki Y, and Akino H (2005) Effects of tolterodine on an overactive bladder depend on suppression of C-fibre bladder afferent activity in rats. J Urol 174: 2032-2036.","DOI":"10.1097\/01.ju.0000176793.50410.9e"},{"key":"10.1124\/jpet.108.145508_bib35","doi-asserted-by":"crossref","unstructured":"Yoshida M, Miyamae K, Iwashita H, Otani M, and Inadome A (2004) Management of detrusor dysfunction in the elderly: changes in acetylcholine and adenosine triphosphate release during aging. Urology 63: 17-23.","DOI":"10.1016\/j.urology.2003.11.003"},{"key":"10.1124\/jpet.108.145508_bib36","doi-asserted-by":"crossref","unstructured":"Yoshida M, Inadome A, Maeda Y, Satoji Y, Masunaga K, Sugiyama Y, and Murakami S (2006) Non-neuronal cholinergic system in human bladder urothelium. Urology 67: 425-430.","DOI":"10.1016\/j.urology.2005.08.014"},{"key":"10.1124\/jpet.108.145508_bib37","doi-asserted-by":"crossref","unstructured":"Zinner N, Gittelman M, Harris R, Susset J, Kanelos A, and Auerbach S (2004) Trospium chloride improves overactive bladder symptoms: a multicentre phase III trial. J Urol 171: 2311-2315.","DOI":"10.1097\/01.ju.0000127742.73136.0c"}],"container-title":["The Journal of Pharmacology and Experimental Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524348438?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022356524348438?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/jpet.108.145508","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,19]],"date-time":"2025-02-19T22:52:41Z","timestamp":1740005561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022356524348438"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,3]]},"references-count":37,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2009,3]]}},"alternative-id":["S0022356524348438"],"URL":"https:\/\/doi.org\/10.1124\/jpet.108.145508","relation":{},"ISSN":["0022-3565"],"issn-type":[{"value":"0022-3565","type":"print"}],"subject":[],"published":{"date-parts":[[2009,3]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparison of Receptor Binding Characteristics of Commonly Used Muscarinic Antagonists in Human Bladder Detrusor and Mucosa","name":"articletitle","label":"Article Title"},{"value":"The Journal of Pharmacology and Experimental Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/jpet.108.145508","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2009 The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}